FindTrial
Sign In

"Estudio comparativo, randomizado y de grupos paralelos con PET en pacientes esquizofrénicos de nuevo diagnóstico en tratamiento con Aripiprazol y Risperidona"

"Estudio comparativo, randomizado y de grupos paralelos con PET en pacientes esquizofrénicos de nuevo diagnóstico en tratamiento con Aripiprazol y Risperidona"

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-000980-26-ES
Enrollment
Unknown
Registered
2007-03-16
Start date
2007-05-11
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Trade Name: Abilify Pharmaceutical Form: Tablet

Sponsors

Fundación para la Investigación biomedica del Hospital Gregorio Marañon
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with recent Schizophrenia diagnostic (less than 2 years) according DSM-IV-TR. Age: 18-30 years old Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Comorbility with Axe I DMS-IV. Pregnant and nursing women

Design outcomes

Primary

MeasureTime frame
Main Objective: Quantification by standard uptake units value in brain areas for neuronal metabolic activity (glucose level);Secondary Objective: Treatment efficay and patient tolerability;Primary end point(s):—

Countries

Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026